Table 3. Further Secondary Outcomes at 12-Week and 1-Year Follow-up.
| Variable | Total participants (individual/group), No. | Median (IQR) | Median difference (95% CI) | P value | ||
|---|---|---|---|---|---|---|
| Individual PFMT | Group PFMT | |||||
| Other lower urinary tract symptoms | ||||||
| Micturition, 7-d bladder diary | ||||||
| Baseline | 359 (183/176) | 8.29 (6.29 to 10.14) | 8.5 (6.86 to 10.14) | NA | ||
| After 12-wk treatment | 336 (171/165) | 6.86 (5.57 to 8.29) | 6.57 (5.57 to 8.14) | 0.29 (−0.43 to 0.71) | .63 | |
| At 1-y follow-up | 318 (165/153) | 7.43 (6.14 to 8.71) | 7.00 (5.86 to 8.43) | 0.43 (−0.14 to 0.86) | .88 | |
| At 1-y follow-up (ITT) | 360 (183/177) | 7.29 (6.07 to 8.64) | 7.00 (5.71 to 8.43) | 0.29 (−0.14 to 0.86) | .86 | |
| Nocturia, >2 episodes per night, No. (%) | ||||||
| Baseline | 362 (184/178) | 59 (32) | 68 (38) | NA | ||
| After treatment | 337 (171/166) | 29 (17) | 35 (21) | −4.00 (−12.00 to 4.00) | .57 | |
| 1-y follow-up | 317 (164/153) | 36 (22) | 38 (25) | −3.00 (−12.00 to 6.00) | .24 | |
| At 1-y follow-up (ITT) | 361 (184/177) | 38 (21) | 46 (26) | −5.00 (−14.00 to 4.00) | .12 | |
| ICIQ-Na | ||||||
| Baseline | 361 (184/177) | 2.00 (1.00 to 4.00) | 3.00 (2.00 to 4.00) | NA | ||
| After treatment | 336 (170/166) | 1.00 (1.00 to 2.00) | 1.00 (1.00 to 2.00) | 0.00 (−1.00 to 1.00) | .13 | |
| 1-y follow-up | 317 (164/153) | 2.00 (1.00 to 3.00) | 2.00 (1.00 to 2.00) | 0.00 (−1.00 to 1.00) | .40 | |
| At 1-y follow-up (ITT) | 362 (184/178) | 2.00 (1.00 to 3.00) | 2.00 (1.00 to 3.00) | 0.00 (−1.00 to 0.50) | .25 | |
| Vaginal and sexual symptoms | ||||||
| ICIQ-VS vaginal symptoms subscaleb | ||||||
| Baseline | 358 (183/175) | 4.00 (0.00 to 9.50) | 4.00 (1.00 to 10.00) | NA | ||
| After 12-wk treatment | 335 (170/165) | 2.00 (0.00 to 6.00) | 2.00 (0.00 to 6.00) | 0.00 (−1.00 to 2.00) | .77 | |
| At 1-y follow-up | 315 (163/152) | 2.00 (0.00 to 5.50) | 0.50 (0.00 to 4.25) | 1.50 (0.00-3.00) | .89 | |
| At 1-y follow-up (ITT) | 362 (184/178) | 2.00 (0.00 to 6.00) | 2.00 (0.00 to 6.00) | 0.00 (−1.50 to 2.00) | .67 | |
| ICIQ-VS sexual matters subscalec | ||||||
| Baseline | 127 (70/57) | 0.00 (0.00 to 25.50) | 0.00 (0.00 to 36.00) | NA | ||
| After 12-wk treatment | 120 (63/57) | 0.00 (0.00 to 5.50) | 0.00 (0.00 to 28.00) | 0.00 (−9.00 to 0.00) | .05 | |
| At 1-y follow-up | 103 (58/45) | 0.00 (0.00 to 10.25) | 0.00 (0.00 to 8.00) | 0.00 (0.00-4.00) | .81 | |
| At 1-y follow-up (ITT) | 160 (87/73) | 0.00 (0.00 to 13.50) | 0.00 (0.00 to 24.00) | 0.00 (−3.00 to 1.00) | .39 | |
| ICIQ-VS quality of life subscaled | ||||||
| Baseline | 361 (184/177) | 0.00 (0.00 to 3.00) | 0.00 (0.00 to 4.00) | NA | ||
| After 12-wk treatment | 334 (169/165) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | .46 | |
| At 1-y follow-up | 314 (163/151) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | .80 | |
| At 1-y follow-up (ITT) | 362 (184/178) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | .47 | |
| ICIQ-FLUTSe | ||||||
| Baseline | 347 (176/171) | 8.00 (2.00 to 8.00) | 8.00 (3.00 to 8.00) | |||
| After 12-wk treatment | 325 (161/164) | 8.00 (1.00 to 8.00) | 8.00 (1.00 to 8.00) | 0.00 (−3.00 to 0.00) | .46 | |
| At 1-y follow-up | 309 (161/148) | 8.00 (1.00 to 8.00) | 8.00 (2.00 to 8.00) | 0.00 (0.00 to 0.00) | .14 | |
| At 1-y follow-up (ITT) | 360 (184/176) | 8.00 (1.00 to 8.00) | 8.00 (2.00 to 8.00) | 0.00 (0.00 to 0.00) | .20 | |
| Self-efficacy | ||||||
| Geriatric self-efficacy indexf | ||||||
| Baseline | 362 (184/178) | 55.00 (41.00 to 69.00) | 59.00 (44.25 to 73.00) | NA | ||
| After 12-wk treatment | 335 (170/165) | 92.00 (79.00 to 104.75) | 95.00 (80.00 to 107.00) | −3.00 (−8.00 to 3.00) | .80 | |
| At 1-y follow-up | 309 (159/150) | 89.00 (70.00 to 102.00) | 93.00 (76.25 to 107.00) | −4.00 (−12.50 to 2.00) | .98 | |
| At 1-y follow-up (ITT) | 362 (184/178) | 86.50 (69.00 to 102.00) | 92.00 (74.00 to 106.75) | −5.50 (−12.50 to 1.50) | .95 | |
Abbreviations: ICIQ, International Consultation on Incontinence Questionnaire; ICIQ-FLUTS, ICIQ-Female Lower Urinary Tract Symptoms Associated With Sexual Matters; ICIQ-N, ICIQ-Nocturia; ICIQ-VS, ICIQ-Vaginal Symptoms; IQR, interquartile range; ITT, intention to treat; LUT, lower urinary tract; PFMT, pelvic floor muscle training.
a
Score range, 0 to 8; higher values indicate increased symptom severity.
b
Score range, 0 to 53; higher values indicate increased symptom severity.
c
Score range, 0 to 58; higher values indicate increased symptom severity.
d
Score range, 0 to 10; higher values indicate increased symptom severity.
e
Score range, 0 to 14; higher values indicate increased symptom severity.
f
Score range, 0 to 120; higher values indicate higher self-efficacy.